Dr. Olga María Rivero Martín

Emerging Investigator
Research Group on Psychiatry and Neurodegenerative Diseases


Dr. Olga Rivero’s research career focuses on improving our understanding of how risk genes for neuropsychiatric and neurodevelopmental disorders impact on brain function and ultimately on behavior. She is biologist and developed her undergraduate and PhD research career at the Department of Genetics, University of Valencia, with focus on the genetics of schizophrenia. As a postdoctoral researcher, she moved to the Division of Molecular Psychiatry, University of Würzburg, to study the neurobiology of attention deficit / hyperactivity disorder. In Würzburg, she experienced a strong shift to new methodologies and approaches which have enriched her research career to a great extent, ranging from cellular imaging and functional studies, to phenotyping of genetically modified mice at the molecular, cellular and systems levels, always with a translational perspective.

Back to the Spanish academia, Dr. Rivero obtained in 2021 a Miguel Servet Contract to work as Emergent Researcher at the INCLIVA Research Group on Psychiatry and Neurodegenerative Disorders. In this new stage, she will focus in the generation of neuronal cell lines from healthy subjects and first episode of psychosis (FEP) patients, in order to identify biomarkers of psychosis and poor medication response. This project will be supported by Carlos III Health Institute.

In addition, during her whole research career, Dr. Rivero has participated in the publication of 31 manuscripts, (25 of them in the first Quartile, 10 of them as main author) as well as in the supervision of 3 PhD, 1 MD, 7 bachelor and 8 master theses.

Dra. Olga María Rivero Martín
Dr. Olga María Rivero Martín


Prodromal symptoms and the duration of untreated psychosis in first episode of psychosis patients: what differences are there between early vs. adult onset and between schizophrenia vs. bipolar disorder?. Baeza I, de la Serna E, Mezquida G, Cuesta M, Vieta E, Amoretti S, Lobo A, Gonzalez-Pinto A, Diaz-Caneja C, Corripio I, Valli I, Puig O, Mane A, Bioque M, Ayora M, Bernardo M, Castro-Fornieles J, Balanza Martinez V, PEPs Grp. European Child & Adolescent Psychiatry. 2023 Apr 7. doi: 10.1007/s00787-023-02196-7. PMID: 37027026

T-cadherin is a novel regulator of pericyte function during angiogenesis. Dasen B, Pigeot S, Born G, Verrier S, Rivero O, Dittrich P, Martin I, Filippova M. American Journal of Physiology-Cell Physiology. 2023 Apr 1;324(4):C821-C836. doi: 10.1152/ajpcell.00326.2022. PMID: 36802732

The polygenic basis of relapse after a first episode of schizophrenia. Segura A, Prohens L, Gasso P, Rodriguez N, Garcia-Rizo C, Moreno-Izco L, Andreu-Bernabeu A, Zorrilla I, Mane A, Rodriguez-Jimenez R, Roldan A, Sarro S, Ibanez A, Usall J, Saiz P, Cuesta M, Parellada M, Gonzalez-Pinto A, Berrocoso E, Bernardo M, Mas S, Mezquida G, Arbelo N, De Matteis M, Galvan J, Duque Guerra A, Arias I Queralt L, Perez-Bacigalupe M, Gonzalez-Ortega I, Toll A, Casanovas F, Sanchez-Pastor L, Valtuena M, Pomarol-Clotet E, Garcia-Leon M, Butjosa A, Rubio-Abadal E, Ribeiro M, Lopez-Ilundain J, Saiz-Ruiz J, Leon-Quismondo L, Rivero O, Ruiz P, Echevarria R, Garcia-Portilla M. European Neuropsychopharmacology. 2023 Aug 19;75:80-92. doi: 10.1016/j.euroneuro.2023.06.003. PMID: 37603902

The role of BDNF and NGF plasma levels in first-episode schizophrenia: a longitudinal study. Martinez Pinteno A, Mezquida G, Bioque M, Lopez Ilundain JM, Andreu Bernabeu A, Zorrilla I, Mane A, Rodriguez Jimenez R, Corripio I, Sarro S, Ibanez A, Usall J, Rivero O, Gasso P, Leza JC, Cuesta MJ, Parellada M, Gonzalez Pinto A, Berrocoso E, Mas S, Bernardo M. European Neuropsychopharmacology. 2022 Feb 23;57:105-117. doi: 10.1016/j.euroneuro.2022.02.003. PMID: 35219096

Reference: PI22/01985
Title: Desarrollo y caracterización de nuevos modelos preclínicos celulares de medicina personalizada en psicosis
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Olga María Rivero Martín, Mª José Escartí Fabra
Duration: 2023 – 2025
Total budget: 117.370,00 €